Tolerability, efficacy, and safety of bisoprolol vs. Carvedilol in japanese patients with heart failure and reduced ejection fraction: The CIBIS-J trial

CIBIS-J Investigators

Research output: Contribution to journalArticle

Abstract

Background: The comparative tolerability, efficacy, and safety of bisoprolol and carvedilol have not been established in Japanese patients with heart failure and reduced ejection fraction (HFrEF). Methods and Results: The CIBIS-J trial is a multicenter, open-label, non-inferiority randomized controlled trial of bisoprolol vs. carvedilol in 217 patients with HFrEF (EF ≤40%). The primary endpoint was tolerability, defined as reaching and maintaining the maximum maintenance dose (bisoprolol 5 mg/day or carvedilol 20 mg/day) during 48 weeks of treatment. The primary endpoint was achieved in 41.4% of patients in bisoprolol (n=111) and 42.5% in carvedilol (n=106) groups. The non-inferiority of tolerability of bisoprolol compared with carvedilol was not supported, however, neither β-blocker was superior with regard to tolerability. Heart rate (HR) decreased in both groups and its decrease from baseline was significantly greater in the bisoprolol group (20.3 vs. 15.4 beats/min at 24 week, P<0.05). Plasma B-type natriuretic peptide (BNP) levels decreased in both groups and the decrease was significantly greater in the carvedilol group (12.4 vs. 39.0 % at 24 weeks, P<0.05). Conclusions: There were no significant differences between bisoprolol and carvedilol in the tolerability of target doses in Japanese HFrEF patients. The clinical efficacy and safety were also similar despite the greater reduction in HR by bisoprolol and plasma BNP by carvedilol.

Original languageEnglish
Pages (from-to)1269-1277
Number of pages9
JournalCirculation Journal
Volume83
Issue number6
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Bisoprolol
Heart Failure
Safety
Brain Natriuretic Peptide
Heart Rate
carvedilol

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Tolerability, efficacy, and safety of bisoprolol vs. Carvedilol in japanese patients with heart failure and reduced ejection fraction : The CIBIS-J trial. / CIBIS-J Investigators.

In: Circulation Journal, Vol. 83, No. 6, 01.01.2019, p. 1269-1277.

Research output: Contribution to journalArticle

@article{8f61307f71124675a1d1bb49e5b541ad,
title = "Tolerability, efficacy, and safety of bisoprolol vs. Carvedilol in japanese patients with heart failure and reduced ejection fraction: The CIBIS-J trial",
abstract = "Background: The comparative tolerability, efficacy, and safety of bisoprolol and carvedilol have not been established in Japanese patients with heart failure and reduced ejection fraction (HFrEF). Methods and Results: The CIBIS-J trial is a multicenter, open-label, non-inferiority randomized controlled trial of bisoprolol vs. carvedilol in 217 patients with HFrEF (EF ≤40{\%}). The primary endpoint was tolerability, defined as reaching and maintaining the maximum maintenance dose (bisoprolol 5 mg/day or carvedilol 20 mg/day) during 48 weeks of treatment. The primary endpoint was achieved in 41.4{\%} of patients in bisoprolol (n=111) and 42.5{\%} in carvedilol (n=106) groups. The non-inferiority of tolerability of bisoprolol compared with carvedilol was not supported, however, neither β-blocker was superior with regard to tolerability. Heart rate (HR) decreased in both groups and its decrease from baseline was significantly greater in the bisoprolol group (20.3 vs. 15.4 beats/min at 24 week, P<0.05). Plasma B-type natriuretic peptide (BNP) levels decreased in both groups and the decrease was significantly greater in the carvedilol group (12.4 vs. 39.0 {\%} at 24 weeks, P<0.05). Conclusions: There were no significant differences between bisoprolol and carvedilol in the tolerability of target doses in Japanese HFrEF patients. The clinical efficacy and safety were also similar despite the greater reduction in HR by bisoprolol and plasma BNP by carvedilol.",
author = "{CIBIS-J Investigators} and Hiroyuki Tsutsui and Momomura, {Shin Ichi} and Tohru Masuyama and Yoshihiko Saito and Issei Komuro and Toyoaki Murohara and Shintaro Kinugawa",
year = "2019",
month = "1",
day = "1",
doi = "10.1253/circj.CJ-18-1199",
language = "English",
volume = "83",
pages = "1269--1277",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "6",

}

TY - JOUR

T1 - Tolerability, efficacy, and safety of bisoprolol vs. Carvedilol in japanese patients with heart failure and reduced ejection fraction

T2 - The CIBIS-J trial

AU - CIBIS-J Investigators

AU - Tsutsui, Hiroyuki

AU - Momomura, Shin Ichi

AU - Masuyama, Tohru

AU - Saito, Yoshihiko

AU - Komuro, Issei

AU - Murohara, Toyoaki

AU - Kinugawa, Shintaro

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: The comparative tolerability, efficacy, and safety of bisoprolol and carvedilol have not been established in Japanese patients with heart failure and reduced ejection fraction (HFrEF). Methods and Results: The CIBIS-J trial is a multicenter, open-label, non-inferiority randomized controlled trial of bisoprolol vs. carvedilol in 217 patients with HFrEF (EF ≤40%). The primary endpoint was tolerability, defined as reaching and maintaining the maximum maintenance dose (bisoprolol 5 mg/day or carvedilol 20 mg/day) during 48 weeks of treatment. The primary endpoint was achieved in 41.4% of patients in bisoprolol (n=111) and 42.5% in carvedilol (n=106) groups. The non-inferiority of tolerability of bisoprolol compared with carvedilol was not supported, however, neither β-blocker was superior with regard to tolerability. Heart rate (HR) decreased in both groups and its decrease from baseline was significantly greater in the bisoprolol group (20.3 vs. 15.4 beats/min at 24 week, P<0.05). Plasma B-type natriuretic peptide (BNP) levels decreased in both groups and the decrease was significantly greater in the carvedilol group (12.4 vs. 39.0 % at 24 weeks, P<0.05). Conclusions: There were no significant differences between bisoprolol and carvedilol in the tolerability of target doses in Japanese HFrEF patients. The clinical efficacy and safety were also similar despite the greater reduction in HR by bisoprolol and plasma BNP by carvedilol.

AB - Background: The comparative tolerability, efficacy, and safety of bisoprolol and carvedilol have not been established in Japanese patients with heart failure and reduced ejection fraction (HFrEF). Methods and Results: The CIBIS-J trial is a multicenter, open-label, non-inferiority randomized controlled trial of bisoprolol vs. carvedilol in 217 patients with HFrEF (EF ≤40%). The primary endpoint was tolerability, defined as reaching and maintaining the maximum maintenance dose (bisoprolol 5 mg/day or carvedilol 20 mg/day) during 48 weeks of treatment. The primary endpoint was achieved in 41.4% of patients in bisoprolol (n=111) and 42.5% in carvedilol (n=106) groups. The non-inferiority of tolerability of bisoprolol compared with carvedilol was not supported, however, neither β-blocker was superior with regard to tolerability. Heart rate (HR) decreased in both groups and its decrease from baseline was significantly greater in the bisoprolol group (20.3 vs. 15.4 beats/min at 24 week, P<0.05). Plasma B-type natriuretic peptide (BNP) levels decreased in both groups and the decrease was significantly greater in the carvedilol group (12.4 vs. 39.0 % at 24 weeks, P<0.05). Conclusions: There were no significant differences between bisoprolol and carvedilol in the tolerability of target doses in Japanese HFrEF patients. The clinical efficacy and safety were also similar despite the greater reduction in HR by bisoprolol and plasma BNP by carvedilol.

UR - http://www.scopus.com/inward/record.url?scp=85066747919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066747919&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-18-1199

DO - 10.1253/circj.CJ-18-1199

M3 - Article

C2 - 30956267

AN - SCOPUS:85066747919

VL - 83

SP - 1269

EP - 1277

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 6

ER -